ES2166932T3 - Productos intermediarios clave para la preparacion de simvastatina. - Google Patents

Productos intermediarios clave para la preparacion de simvastatina.

Info

Publication number
ES2166932T3
ES2166932T3 ES97107059T ES97107059T ES2166932T3 ES 2166932 T3 ES2166932 T3 ES 2166932T3 ES 97107059 T ES97107059 T ES 97107059T ES 97107059 T ES97107059 T ES 97107059T ES 2166932 T3 ES2166932 T3 ES 2166932T3
Authority
ES
Spain
Prior art keywords
simvastatin
ring
preparation
intermediate products
open
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97107059T
Other languages
English (en)
Inventor
Jag Mohan Khanna
Yatendra Kumar
Rajesh Kumar Thaper
Satyananda Misra
S M Dileep Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Application granted granted Critical
Publication of ES2166932T3 publication Critical patent/ES2166932T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN PROCESO PARA PREPARAR SIMVASTATINA A PARTIR DE LOVASTATINA O ACIDO MEVINOLINICO EN SU FORMA DE SAL INCLUYE TRATAR CUALQUIERA DE LOS MATERIALES DE PARTIDA CON CICLOPROPILO O BUTILAMIDA, ABRIENDOSE DE ESE MODO EL ANILLO PIRANONA CUANDO EL MATERIAL DE PARTIDA ES LOVASTATINA, AÑADIR UN GRUPO METILO A LA CADENA LATERAL 2 - METILBUTIRATO, Y POSTERIORMENTE CERRAR EL ANILLO PIRANONA ABIERTO PARA PRODUCIR SIMVASTATINA. EL PROCESO SE REALIZA SIN PROTEGER Y DESPROTEGER LOS DOS GRUPOS HIDROXI DEL ANILLO PIRANONA ABIERTO. EN UNA REALIZACION PREFERIDA, SE TRATA EL MATERIAL DE PARTIDA CON CICLOPROPILAMINA, LO CUAL PRODUCE SIMVASTATINA VIA EL NUEVO INTERMEDIO CICLOPROPILAMIDA DE LOVASTATINA.
ES97107059T 1997-03-13 1997-04-29 Productos intermediarios clave para la preparacion de simvastatina. Expired - Lifetime ES2166932T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/816,574 US5763653A (en) 1997-03-13 1997-03-13 Key intermediates in the manufacture of simvastatin

Publications (1)

Publication Number Publication Date
ES2166932T3 true ES2166932T3 (es) 2002-05-01

Family

ID=25221008

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97107059T Expired - Lifetime ES2166932T3 (es) 1997-03-13 1997-04-29 Productos intermediarios clave para la preparacion de simvastatina.

Country Status (9)

Country Link
US (1) US5763653A (es)
EP (1) EP0864560B1 (es)
AT (1) ATE209627T1 (es)
CZ (1) CZ286576B6 (es)
DE (1) DE69708591T2 (es)
ES (1) ES2166932T3 (es)
SI (1) SI9700203A (es)
SK (1) SK282909B6 (es)
ZA (1) ZA974022B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0940395A1 (en) * 1998-03-05 1999-09-08 Synthon B.V. Process for producing simvastatin and/or its derivatives
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
CN1226296C (zh) * 1998-12-10 2005-11-09 钟渊化学工业株式会社 制备辛伐他汀的方法
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
US6573385B1 (en) 1999-11-11 2003-06-03 Biocon India Limited Process for manufacturing simvastatin and novel intermediates thereof
AU2127500A (en) 1999-11-11 2001-06-06 Biocon India Limited Process for manufacturing simvastatin and the novel intermediates
AU2001228796A1 (en) * 2000-09-13 2002-04-02 Biocon India Limited Process for manufacturing simvastatin and the novel intermediates
KR100502833B1 (ko) * 2002-03-25 2005-07-25 보령제약 주식회사 심바스타틴 및 이의 중간체 화합물들의 개선된 제조방법
SI21187A (sl) 2002-03-26 2003-10-31 Krka, Tovarna Zdravil D.D., Novo Mesto Postopek za pripravo 4-oksitetrahidropiran-2-onov
US6603022B1 (en) 2002-05-10 2003-08-05 Biocon India Limited Process for manufacturing Simvastatin and novel intermediates thereof
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US6995277B2 (en) 2003-02-11 2006-02-07 Plus Chemicals, B.V. Process for preparing simvastatin having controlled ranges of simvastatin dimer content
KR20040092790A (ko) * 2003-04-29 2004-11-04 씨제이 주식회사 심바스타틴 중간체 제조방법
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
CN1754870A (zh) * 2004-09-30 2006-04-05 淮北市辉克药业有限公司 辛伐他汀的制备方法
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
ES2524725T3 (es) 2009-09-30 2014-12-11 Codexis, Inc. Polipéptidos LovD variantes y sus usos.
SG10201504099WA (en) 2009-10-08 2015-06-29 Univ California LovD MUTANTS EXHIBITING IMPROVED PROPERTIES TOWARDS SIMVASTATIN SYNTHESIS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (es) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4293496A (en) * 1980-02-04 1981-10-06 Merck & Co., Inc. 6(R)-[2-(8-Hydroxy-2,6-dimethylpolyhydronaphthyl-1)-ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-ones
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4584389A (en) * 1983-10-11 1986-04-22 Merck & Co., Inc. Processes for preparing 6(R)-[2-[8(S)(2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-decahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one
US4582915A (en) * 1983-10-11 1986-04-15 Merck & Co., Inc. Process for C-methylation of 2-methylbutyrates
US4611081A (en) * 1985-07-05 1986-09-09 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors intermediates
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4908452A (en) * 1987-12-21 1990-03-13 Merck & Co., Inc. Process for preparing nitriles
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5159104A (en) * 1991-05-01 1992-10-27 Merck & Co., Inc. Process to simvastatin ester
US5393893A (en) * 1993-11-08 1995-02-28 Apotex, Inc. Process for producing simvastatin and analogs thereof

Also Published As

Publication number Publication date
SK282909B6 (sk) 2003-01-09
SK116597A3 (en) 1999-05-07
EP0864560A1 (en) 1998-09-16
ZA974022B (en) 1997-12-09
US5763653A (en) 1998-06-09
CZ265097A3 (cs) 1998-09-16
SI9700203A (sl) 1998-10-31
CZ286576B6 (cs) 2000-05-17
EP0864560B1 (en) 2001-11-28
DE69708591T2 (de) 2002-08-01
DE69708591D1 (de) 2002-01-10
ATE209627T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
ES2166932T3 (es) Productos intermediarios clave para la preparacion de simvastatina.
DE69534130D1 (de) Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen.
DE69729587D1 (de) Behandlung von migränekopfschmerzen mit metoclopramid und einem nsaid
ATE515513T1 (de) Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten
DE60013827D1 (de) Vorrichtung zum behandeln von schlachtprodukten
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
ATE403437T1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
DE60043308D1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
DE602004003587D1 (de) Kosmetische verwendung einer zusammensetzung mit mindestens einem oxazolin als wirkstoff, als abnehmprodukt und/oder zur prävention und/oder behandlung von cellulite
WO2004016256A3 (en) AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
BR9305083A (pt) Dispositivo de transporte para máquinas, para o tratamento de garrafas ou recipientes semelhantes
PT942815E (pt) Metodo de utilizacao de materiais compositos lenhocelulosicos reciclados
DE50208897D1 (de) Vorrichtung zum abschwarten und enthäuten von behandlungsgut
BR9813666A (pt) Processos para preparar uma composição farmacêutica e para tratamento de pacientes, e, composição farmacêutica
IL153557A0 (en) Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
AR110470A1 (es) Terapia de combinación para tratar la enfermedad de alzheimer
DE69121598T2 (de) Verfahren, um das Verpacken von sterilisiertem Mineralwasser vorzubereiten sowie verpacktes, sterilisiertes Mineralwasser
EA200100785A1 (ru) Шипучие слабительные средства
MXPA05004121A (es) Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
Luszczki et al. Effect of N-(m-bromoanilinomethyl)-p-isopropoxyphenylsuccinimide on the anticonvulsant action of four classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model
DE50015379D1 (de) Vorrichtung zur Überkopf-Behandlung von Flaschen oder dergleichen Behältern
TW200509882A (en) Beauty method
DE69910332D1 (de) Sicherheitsvorrichtung, insbesondere zum Schutz von Bereichen
DE69403197D1 (de) Die verwendung von anti-helminth impfstoffen zur kontrolle von parasitären krankheiten, die mit einem verlust der natürlichen immunität assoziiert sind